A Phase II Trial of Metronomic Dosing of Etoposide and Cyclophosphamide in Patients With Stage D0 Prostate Cancer
- Determine the prostate-specific antigen response in patients with stage D0 prostate
cancer treated with low-dose etoposide and cyclophosphamide.
- Determine the toxic effects of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive low-dose oral etoposide once daily on days 1-21 and low-dose oral
cyclophosphamide once daily on days 22-42. Treatment repeats every 42 days for up to 4
courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 8-12 weeks until disease
PROJECTED ACCRUAL: A total of 14-39 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Prostate-specific antigen response
Mark Stein, MD
Cancer Institute of New Jersey
United States: Federal Government
|Overlook Hospital||Summit, New Jersey 07902-0220|
|Carol G. Simon Cancer Center at Morristown Memorial Hospital||Morristown, New Jersey 07962|
|Cancer Institute of New Jersey at Hamilton||Hamilton, New Jersey 08690|
|Saint Peter's University Hospital||New Brunswick, New Jersey 08901-1780|
|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School||New Brunswick, New Jersey 08903|
|Mountainside Hospital Cancer Center||Montclair, New Jersey 07042|
|Central Jersey Oncology Center, PA - East Brunswick||East Brunswick, New Jersey 08816|